ARCAPTA NEOHALER
Total Payments
$119,762
Transactions
80
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $140.00 | 1 | 0 |
| 2019 | $5,391 | 26 | 1 |
| 2018 | $7,538 | 25 | 0 |
| 2017 | $106,692 | 28 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $119,630 | 77 | 99.9% |
| Food and Beverage | $131.97 | 3 | 0.1% |
Payments by Type
Research
$119,630
77 transactions
General
$131.97
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FIRST IN HUMAN SINGLE AND MULTIPLE DOSE ESCALATION STUDY OF QAS523 FOR SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY ADULT AND OLDER VOLUNTEERS | Novartis Pharmaceuticals Corporation | $99,194 | 0 |
| A 12 WEEK TREATMENT MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY INDACATEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD | Novartis Pharmaceuticals Corporation | $4,992 | 0 |
| A 12 WEEK TREATMENT MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY INDACATEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD | Novartis Pharmaceuticals Corporation | $4,092 | 0 |
| A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF DIFFERENT DOSES OF INDACATEROL IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING SALMETEROL AS AN ACTIVE CONTROL | Novartis Pharmaceuticals Corporation | $3,456 | 0 |
| A 12 WEEK TREATMENT MULTI CENTRE RANDOMIZED PARALLEL GROUP BLINDED DOUBLE DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF INDACATEROL 150 UG OD DELIVERED VIA A SDDPI USING TIOTROPIUM 18 UG OD DELIVERED VIA A HANDIHALER IN PATIENTS WITH MODERATE TO SEVERE COPD | Novartis Pharmaceuticals Corporation | $2,304 | 0 |
| A RANDOMIZED DOUBLE BLIND CONTROLLED PARALLEL GROUP 12 WEEK TREATMENT STUDY TO COMPARE THE EFFICACY AND SAFETY OF THE COMBINATION OF INDACATEROL 150 UG ONCE DAILY WITH OPEN LABEL TIOTROPIUM 18 UG ONCE DAILY VERSUS OPEN LABEL TIOTROPIUM 18 UG ONCE DAILY IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Novartis Pharmaceuticals Corporation | $1,610 | 0 |
| A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF DIFFERENT DOSES OF INDACATEROL IN ADULT PATIENTS WITH PERSISTENT ASTHMA USING SALMETEROL AS AN ACTIVE CONTROL | Novartis Pharmaceuticals Corporation | $1,152 | 0 |
| A RANDOMIZED DOUBLE BLIND DOUBLE DUMMY PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF DIFFERENT DOSES OF INDACATEROL IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING SALMETEROL AS AN ACTIVE CONT | Novartis Pharmaceuticals Corporation | $1,152 | 0 |
| A RANDOMIZED DOUBLE BLIND CONTROLLED PARALLEL GROUP 12 WEEK TREATMENT STUDY TO COMPARE THE EFFICACY AND SAFETY OF THE COMBINATION OF INDACATEROL 150 UG ONCE DAILY WITH OPEN LABEL TIOTROPIUM 18 UG ONCE DAILY VERSUS OPEN LABEL TIOTROPIUM 18 UG ONCE DAILY IN | Novartis Pharmaceuticals Corporation | $910.00 | 0 |
| A 12 WEEK TREATMENT MULTI CENTRE RANDOMIZED PARALLEL GROUP BLINDED DOUBLE DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF INDACATEROL 150 UG OD DELIVERED VIA A SDDPI USING TIOTROPIUM 18 UG OD DELIVERED VIA A HANDIHALER IN PATIENTS WITH MODERATE TO SEVER | Novartis Pharmaceuticals Corporation | $768.00 | 0 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $119,762
Product Information
- Type Drug
- Total Payments $119,762
- Total Doctors 3
- Transactions 80
About ARCAPTA NEOHALER
ARCAPTA NEOHALER is a drug associated with $119,762 in payments to 3 healthcare providers, recorded across 80 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $140.00 was paid across 1 transactions to 0 doctors.
The most common payment nature for ARCAPTA NEOHALER is "Unspecified" ($119,630, 99.9% of total).
ARCAPTA NEOHALER is associated with 10 research studies, including "FIRST IN HUMAN SINGLE AND MULTIPLE DOSE ESCALATION STUDY OF QAS523 FOR SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS IN HEALTHY ADULT AND OLDER VOLUNTEERS" ($99,194).